Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a rural HIV clinic in Kenya

AIDS Research and Human Retroviruses

Volumn 29, Issue 1, 2013, Pages 129-135

  Hassan, Amin S ^a   Mwaringa, Shalton M ^a   Obonyo, Clare A ^b   Nabwera, Helen M ^a   Sanders, Eduard J ^a,c   Rinke De Wit, Tobias F ^d,e   Cane, Patricia A ^f   Berkley, James A ^a,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b Kilifi District Hospital   (Kenya)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PharmAccess Foundation   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SURVEILLANCE; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; KENYA; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; RURAL HEALTH CARE; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALE; MOLECULAR SEQUENCE DATA; PREVALENCE; RURAL POPULATION;

EID: 84871884858     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0167     Document Type: Article

References (39)

1. WHO, UNAIDS, UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report 2010 (cited 18 January 2012). Available from http://www.who.int/hiv/pub/2010progress report/key-facts-en.pdf.
2. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, Munthali F, et al.: Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008;371(9624): 1603-1611.
3. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther 2008;13(Suppl 2):25-36.
4. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al.: Virological monitoring and resistance to firstline highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: A systematic review and meta-analysis. Lancet Infect Dis 2009;9(7): 409-417.
5. Hamers RL, Derdelinckx I, van Vugt M, Stevens W, Rinke de Wit TF, and Schuurman R: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antiviral Ther 2008;13(5):625-639.
6. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, et al.: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: A multicentre cohort study. Lancet Infect Dis 2012; 12(4):307-317.
7. Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA, 3rd, Shikuma C, et al.: Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008;197(6):867-870.
8. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al.: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011;11(5):363-371.
9. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, et al.: Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antiviral Ther 2008;13(Suppl 2):101-107.
10. Bussmann H, de la Hoz Gomez F, Roels TH, Wester CW, Bodika SM, Moyo S, et al.: Prevalence of transmitted HIV drug resistance in Botswana: Lessons learned from the HIVDR-Threshold Survey conducted among women presenting for routine antenatal care as part of the 2007 national sentinel survey. AIDS Res Hum Retroviruses 2011;27(4): 365-372.
11. Ndembi N, Lyagoba F, Nanteza B, Kushemererwa G, Serwanga J, Katongole-Mbidde E, et al.: Transmitted antiretroviral drug resistance surveillance among newly HIV type 1-diagnosed women attending an antenatal clinic in Entebbe, Uganda. AIDS Res Hum Retroviruses 2008;24(6): 889-895.
12. Parboosing R, Naidoo A, Gordon M, Taylor M, and Vella V: Resistance to antiretroviral drugs in newly diagnosed, young treatment-naive HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa. J Med Virol 2011; 83(9):1508-1513.
13. Somi GR, Kibuka T, Diallo K, Tuhuma T, Bennett DE, Yang C, et al.: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. Antiviral Ther 2008;13(Suppl 2):77-82.
14. Abegaz WE, Grossman Z, Wolday D, Ram D, Kaplan J, Sibide K, et al.: Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. Antiviral Ther 2008;13(Suppl 2): 89-94.
15. Kamoto K and Aberle-Grasse J: Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antiviral Ther 2008;13(Suppl 2):83-87.
16. Ndembi N, Hamers RL, Sigaloff KC, Lyagoba F, Magambo B, Nanteza B, et al.: Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS (London) 2011;25(7):905-910.
17. Price MA, Wallis CL, Lakhi S, Karita E, Kamali A, Anzala O, et al.: Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011;27(1):5-12.
18. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, et al.: HIV-1 drug resistance in antiretroviralnaive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11(10):750-759.
19. Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem- Tambe A, Butel C, et al.: Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients. AIDS (London) 2011;25(17):2183-2188.
20. Lihana RW, Khamadi SA, Lubano K, Lwembe R, Kiptoo MK, Lagat N, et al.: HIV type 1 subtype diversity and drugresistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses 2009;25(12):1211-1217.
21. Sigaloff KC, Mandaliya KN, Hamers RL, Otieno FP, Jao IM, Lyagoba F, et al.: High prevalence of transmitted antiretroviral drug resistance among newly HIV-1 diagnosed adults in Mombasa, Kenya. AIDS Res Hum Retroviruses 2012;28(9):833-837.
22. Kenya National Bureau of Statistics (KNBS) and ICF Macro. 2010. Kenya Demographic and Health Survey 2008-09 (cited 18 January 2012). Available from http://www.measure dhs.com/pubs/pdf/FR229/FR229.pdf.
23. National AIDS and STI Control Programme (NASCOP): Guidelines for antiretroviral therapy in Kenya. 2011 (cited 18 January 2012). Available from http://nascop.or.ke/library/ artconference/Kenya-Treatment-Guidelines.pdf.
24. Hue S, Hassan AS, Nabwera H, Sanders EJ, Pillay D, Berkley JA, et al.: HIV Type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination. AIDS Res Hum Retroviruses 2012;28(2):220-224.
25. Hassan AS, Fielding KL, Thuo NM, Nabwera HM, Snaders EJ, and Berkley JA: Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: A cohort study. Trop Med Int Health 2012;17(1):82-93.
26. Cane P: HIV drug resistance testing. Methods Mol Biol 2011;665:123-132
27. Dunn DT, Coughlin K, and Cane PA: Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS 2011; 6(4):251-257.
28. Kosakovsky Pond SL, Posada D, Stawiski E, Chappey C, Poon AF, Hughes G, et al.: An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comp Biol 2009; 5(11):e1000581.
29. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PloS One 2009;4(3):e4724.
30. Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatmentnaive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40(3):468-474.
31. Baggaley RF, Ferguson NM, and Garnett GP: The epidemiological impact of antiretroviral use predicted by mathematical models: A review. Emerging Themes Epidemiol 2005;2:9.
32. Baggaley RF, Garnett GP, and Ferguson NM: Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006;3(4):e124.
33. Blower S, Bodine E, Kahn J, and McFarland W: The antiretroviral rollout and drug-resistant HIV in Africa: Insights from empirical data and theoretical models. AIDS (London) 2005;19(1):1-14.
34. Mosha F, Urassa W, Aboud S, Lyamuya E, Sandstrom E, Bredell H, et al.: Prevalence of genotypic resistance to antiretroviral drugs in treatment-naive youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2011;27(4):377-382.
35. Lihana RW, Khamadi SA, Lwembe RM, Ochieng W, Kinyua JG, Kiptoo MK, et al.: The changing trend of HIV type 1 subtypes in Nairobi. AIDS Res Hum Retroviruses 2009; 25(3):337-342.
36. Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, et al.: Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82(11):5510-5518.
37. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, et al.: Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (London) 2004; 18(12):1653-1660.
38. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, et al.: Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004;37(5):1570-1573.
39. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al.: HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS (London) 2007;21(2):215-223